CN117843736A - Novel variant of transport protein and method for producing L-aromatic amino acid using same - Google Patents
Novel variant of transport protein and method for producing L-aromatic amino acid using same Download PDFInfo
- Publication number
- CN117843736A CN117843736A CN202311729862.3A CN202311729862A CN117843736A CN 117843736 A CN117843736 A CN 117843736A CN 202311729862 A CN202311729862 A CN 202311729862A CN 117843736 A CN117843736 A CN 117843736A
- Authority
- CN
- China
- Prior art keywords
- amino acid
- primer
- transporter
- variant
- aromatic amino
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 31
- 108010078791 Carrier Proteins Proteins 0.000 title abstract description 45
- 102000014914 Carrier Proteins Human genes 0.000 title description 15
- 150000001413 amino acids Chemical class 0.000 claims abstract description 49
- FVTCRASFADXXNN-SCRDCRAPSA-N flavin mononucleotide Chemical compound OP(=O)(O)OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O FVTCRASFADXXNN-SCRDCRAPSA-N 0.000 claims abstract description 25
- 101710125177 FAD transporter Proteins 0.000 claims abstract description 20
- 229940024606 amino acid Drugs 0.000 claims description 61
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 40
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims description 36
- 229960005190 phenylalanine Drugs 0.000 claims description 19
- 108091033319 polynucleotide Proteins 0.000 claims description 16
- 102000040430 polynucleotide Human genes 0.000 claims description 16
- 239000002157 polynucleotide Substances 0.000 claims description 16
- 238000000034 method Methods 0.000 claims description 14
- 241000588722 Escherichia Species 0.000 claims description 9
- 239000004471 Glycine Substances 0.000 claims description 9
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims description 5
- 238000012258 culturing Methods 0.000 claims description 5
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims description 5
- 229960004441 tyrosine Drugs 0.000 claims description 3
- IFGCUJZIWBUILZ-UHFFFAOYSA-N sodium 2-[[2-[[hydroxy-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyphosphoryl]amino]-4-methylpentanoyl]amino]-3-(1H-indol-3-yl)propanoic acid Chemical compound [Na+].C=1NC2=CC=CC=C2C=1CC(C(O)=O)NC(=O)C(CC(C)C)NP(O)(=O)OC1OC(C)C(O)C(O)C1O IFGCUJZIWBUILZ-UHFFFAOYSA-N 0.000 claims description 2
- 108090000623 proteins and genes Proteins 0.000 abstract description 46
- 229930024421 Adenine Natural products 0.000 abstract description 22
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 abstract description 22
- 229960000643 adenine Drugs 0.000 abstract description 22
- 102100039338 Aminomethyltransferase, mitochondrial Human genes 0.000 abstract description 18
- 108050001492 Ammonium transporters Proteins 0.000 abstract description 18
- 102000004169 proteins and genes Human genes 0.000 abstract description 11
- 230000000694 effects Effects 0.000 abstract description 10
- 244000005700 microbiome Species 0.000 abstract description 8
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 235000001014 amino acid Nutrition 0.000 description 57
- 239000002609 medium Substances 0.000 description 43
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 35
- 239000013598 vector Substances 0.000 description 34
- 210000004027 cell Anatomy 0.000 description 25
- 239000012634 fragment Substances 0.000 description 25
- 241000588724 Escherichia coli Species 0.000 description 24
- 239000011768 flavin mononucleotide Substances 0.000 description 23
- FVTCRASFADXXNN-UHFFFAOYSA-N flavin mononucleotide Natural products OP(=O)(O)OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O FVTCRASFADXXNN-UHFFFAOYSA-N 0.000 description 23
- 235000019231 riboflavin-5'-phosphate Nutrition 0.000 description 23
- 229960004799 tryptophan Drugs 0.000 description 21
- 239000013612 plasmid Substances 0.000 description 20
- 239000007787 solid Substances 0.000 description 18
- 238000011144 upstream manufacturing Methods 0.000 description 18
- CKLJMWTZIZZHCS-REOHCLBHSA-N aspartic acid group Chemical group N[C@@H](CC(=O)O)C(=O)O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 15
- 229930027917 kanamycin Natural products 0.000 description 14
- 229960000318 kanamycin Drugs 0.000 description 14
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 14
- 229930182823 kanamycin A Natural products 0.000 description 14
- 230000014509 gene expression Effects 0.000 description 10
- 239000007788 liquid Substances 0.000 description 10
- 235000018102 proteins Nutrition 0.000 description 10
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 9
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 9
- 230000003321 amplification Effects 0.000 description 9
- 238000000137 annealing Methods 0.000 description 9
- 238000004925 denaturation Methods 0.000 description 9
- 230000036425 denaturation Effects 0.000 description 9
- 238000003199 nucleic acid amplification method Methods 0.000 description 9
- 238000006116 polymerization reaction Methods 0.000 description 9
- 230000010076 replication Effects 0.000 description 9
- 239000000126 substance Substances 0.000 description 8
- 101100054918 Escherichia coli (strain K12) adeQ gene Proteins 0.000 description 7
- 229960000723 ampicillin Drugs 0.000 description 7
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 6
- 230000001105 regulatory effect Effects 0.000 description 6
- 101150035667 yeeO gene Proteins 0.000 description 6
- -1 aromatic amino acids Chemical class 0.000 description 5
- 235000019162 flavin adenine dinucleotide Nutrition 0.000 description 5
- 239000011714 flavin adenine dinucleotide Substances 0.000 description 5
- 238000003780 insertion Methods 0.000 description 5
- 230000037431 insertion Effects 0.000 description 5
- 239000002773 nucleotide Substances 0.000 description 5
- 125000003729 nucleotide group Chemical group 0.000 description 5
- 238000013518 transcription Methods 0.000 description 5
- 230000035897 transcription Effects 0.000 description 5
- 230000009466 transformation Effects 0.000 description 5
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 4
- 108020004705 Codon Proteins 0.000 description 4
- 101150001904 amtB gene Proteins 0.000 description 4
- 235000003704 aspartic acid Nutrition 0.000 description 4
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 4
- 238000010367 cloning Methods 0.000 description 4
- 210000003527 eukaryotic cell Anatomy 0.000 description 4
- 229920001184 polypeptide Polymers 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 230000008685 targeting Effects 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 241000660147 Escherichia coli str. K-12 substr. MG1655 Species 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 108091092584 GDNA Proteins 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- 125000000539 amino acid group Chemical group 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 125000000404 glutamine group Chemical group N[C@@H](CCC(N)=O)C(=O)* 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 210000001236 prokaryotic cell Anatomy 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 108091006146 Channels Proteins 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 108091029865 Exogenous DNA Proteins 0.000 description 2
- 238000012366 Fed-batch cultivation Methods 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 2
- 241000588717 Shimwellia blattae Species 0.000 description 2
- 241000193996 Streptococcus pyogenes Species 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 108091023040 Transcription factor Proteins 0.000 description 2
- 102000040945 Transcription factor Human genes 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 101150031414 ambB gene Proteins 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 238000012365 batch cultivation Methods 0.000 description 2
- 239000001110 calcium chloride Substances 0.000 description 2
- 229910001628 calcium chloride Inorganic materials 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- VWWQXMAJTJZDQX-UYBVJOGSSA-N flavin adenine dinucleotide Chemical compound C1=NC2=C(N)N=CN=C2N1[C@@H]([C@H](O)[C@@H]1O)O[C@@H]1CO[P@](O)(=O)O[P@@](O)(=O)OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C2=NC(=O)NC(=O)C2=NC2=C1C=C(C)C(C)=C2 VWWQXMAJTJZDQX-UYBVJOGSSA-N 0.000 description 2
- 229940013640 flavin mononucleotide Drugs 0.000 description 2
- 229940093632 flavin-adenine dinucleotide Drugs 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 150000007523 nucleic acids Chemical group 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- 241000701161 unidentified adenovirus Species 0.000 description 2
- DIGQNXIGRZPYDK-WKSCXVIASA-N (2R)-6-amino-2-[[2-[[(2S)-2-[[2-[[(2R)-2-[[(2S)-2-[[(2R,3S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S,3S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2R)-2-[[2-[[2-[[2-[(2-amino-1-hydroxyethylidene)amino]-3-carboxy-1-hydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1,5-dihydroxy-5-iminopentylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]hexanoic acid Chemical compound C[C@@H]([C@@H](C(=N[C@@H](CS)C(=N[C@@H](C)C(=N[C@@H](CO)C(=NCC(=N[C@@H](CCC(=N)O)C(=NC(CS)C(=N[C@H]([C@H](C)O)C(=N[C@H](CS)C(=N[C@H](CO)C(=NCC(=N[C@H](CS)C(=NCC(=N[C@H](CCCCN)C(=O)O)O)O)O)O)O)O)O)O)O)O)O)O)O)N=C([C@H](CS)N=C([C@H](CO)N=C([C@H](CO)N=C([C@H](C)N=C(CN=C([C@H](CO)N=C([C@H](CS)N=C(CN=C(C(CS)N=C(C(CC(=O)O)N=C(CN)O)O)O)O)O)O)O)O)O)O)O)O DIGQNXIGRZPYDK-WKSCXVIASA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- PAWQVTBBRAZDMG-UHFFFAOYSA-N 2-(3-bromo-2-fluorophenyl)acetic acid Chemical compound OC(=O)CC1=CC=CC(Br)=C1F PAWQVTBBRAZDMG-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 239000004254 Ammonium phosphate Substances 0.000 description 1
- 101100323184 Aquifex aeolicus (strain VF5) amt gene Proteins 0.000 description 1
- 241000588732 Atlantibacter hermannii Species 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 101100162669 Bacillus subtilis (strain 168) nrgA gene Proteins 0.000 description 1
- 241000193388 Bacillus thuringiensis Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 239000002028 Biomass Substances 0.000 description 1
- 108091033409 CRISPR Proteins 0.000 description 1
- 102000034573 Channels Human genes 0.000 description 1
- 241000186031 Corynebacteriaceae Species 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N DMSO Substances CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 241001240954 Escherichia albertii Species 0.000 description 1
- 101100431983 Escherichia coli (strain K12) yeeO gene Proteins 0.000 description 1
- 241000588720 Escherichia fergusonii Species 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 101100321817 Human parvovirus B19 (strain HV) 7.5K gene Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 150000008575 L-amino acids Chemical class 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 108090000157 Metallothionein Proteins 0.000 description 1
- 102000003792 Metallothionein Human genes 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 241000588733 Pseudescherichia vulneris Species 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 235000004443 Ricinus communis Nutrition 0.000 description 1
- 101100221606 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) COS7 gene Proteins 0.000 description 1
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 1
- 241000607715 Serratia marcescens Species 0.000 description 1
- 235000019764 Soybean Meal Nutrition 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 239000001099 ammonium carbonate Substances 0.000 description 1
- 235000012501 ammonium carbonate Nutrition 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- 229910000148 ammonium phosphate Inorganic materials 0.000 description 1
- 235000019289 ammonium phosphates Nutrition 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 238000012870 ammonium sulfate precipitation Methods 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 239000002518 antifoaming agent Substances 0.000 description 1
- 229940097012 bacillus thuringiensis Drugs 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 230000006696 biosynthetic metabolic pathway Effects 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 229960005091 chloramphenicol Drugs 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 239000013601 cosmid vector Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 238000012364 cultivation method Methods 0.000 description 1
- 238000012136 culture method Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- MNNHAPBLZZVQHP-UHFFFAOYSA-N diammonium hydrogen phosphate Chemical compound [NH4+].[NH4+].OP([O-])([O-])=O MNNHAPBLZZVQHP-UHFFFAOYSA-N 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 238000007599 discharging Methods 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000003630 growth substance Substances 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 150000002484 inorganic compounds Chemical class 0.000 description 1
- 229910010272 inorganic material Inorganic materials 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 229910000358 iron sulfate Inorganic materials 0.000 description 1
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 235000020778 linoleic acid Nutrition 0.000 description 1
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 229920001522 polyglycol ester Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000004952 protein activity Effects 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000004455 soybean meal Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 235000020238 sunflower seed Nutrition 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 230000005030 transcription termination Effects 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 230000014621 translational initiation Effects 0.000 description 1
- 125000000430 tryptophan group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C2=C([H])C([H])=C([H])C([H])=C12 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
- C07K14/245—Escherichia (G)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P13/00—Preparation of nitrogen-containing organic compounds
- C12P13/04—Alpha- or beta- amino acids
- C12P13/22—Tryptophan; Tyrosine; Phenylalanine; 3,4-Dihydroxyphenylalanine
Abstract
The present invention relates to a novel variant of a transporter, which alters the activity of a protein by substituting one or more amino acids constituting the amino acid sequence of an ammonium transporter, an adenine transporter or an FMN/FAD transporter, so that a recombinant microorganism comprising the same can efficiently produce an L-aromatic amino acid, and a method for producing an L-aromatic amino acid using the same.
Description
The present invention is a divisional application filed for the application of 2023, 02, 14, 202380008895.0, titled "novel variant of transport protein and method for producing L-aromatic amino acid by using the same".
Technical Field
The present invention relates to novel variants of transport proteins and methods for producing L-aromatic amino acids using the same.
Background
Amino acids are classified into hydrophobic, hydrophilic, basic and acidic amino acids according to the nature of side chains, and amino acids having benzene rings therein are called aromatic amino acids. Among the aromatic amino acids, phenylalanine, tyrosine and tryptophan are essential amino acids that cannot be synthesized in living bodies, and belong to the high value-added industry that forms a market of $3000 million each year worldwide.
The production of aromatic amino acids can be carried out using wild-type strains obtained in a natural state or variant strains modified in such a manner as to enhance the amino acid productivity. In recent years, in order to improve the production efficiency of aromatic amino acids, genetic recombination techniques have been applied to microorganisms such as E.coli and coryneform bacteria which are used in many cases for producing useful substances such as L-amino acids, and various recombinant strains or variants having excellent L-aromatic amino acid productivity have been developed, and a method for producing L-aromatic amino acids using the same. In particular, the following attempts were made: the production of the corresponding amino acid is increased by targeting genes such as enzymes, transcription factors, transport proteins, etc. involved in the biosynthesis pathway of the L-aromatic amino acid, or inducing mutation in promoters regulating their expression. However, since the types of proteins such as enzymes, transcription factors, transport proteins, etc., which are directly or indirectly involved in the production of L-aromatic amino acids, are several tens of kinds, a great deal of research is actually required as to whether the L-aromatic amino acid production capacity is increased or not according to the activity change of such proteins.
Prior art literature
Patent literature
Korean patent No. 10-1830002
Disclosure of Invention
The object of the present invention is to provide novel transport protein variants.
In addition, the present invention provides polynucleotides encoding the above variants.
In addition, the present invention provides a transformant comprising the above variant or polynucleotide.
The present invention also provides a method for producing an L-aromatic amino acid using the transformant.
One embodiment of the present invention provides a variant selected from the following variants: an ammonium transporter variant consisting of the amino acid sequence of SEQ ID NO. 1, wherein glycine 363 of the amino acid sequence of SEQ ID NO. 3 is replaced with aspartic acid; an adenine transporter variant consisting of the amino acid sequence of SEQ ID NO. 5, wherein tryptophan No. 136 in the amino acid sequence of SEQ ID NO. 7 is replaced with a stop codon; and FMN/FAD transporter variants consisting of the amino acid sequence of SEQ ID NO. 9, wherein glycine 272 of the amino acid sequence of SEQ ID NO. 11 is replaced with glutamine.
As used herein, a "transporter" is a generic term for proteins responsible for moving various substances such as ions, chemicals, and proteins through a cell membrane, and is specific to the transported substance. Such transporter proteins are broadly classified into channel proteins that form a movement channel penetrating through inner and outer pores in a membrane to become a substance, and transporter proteins that move a binding site of a transported substance across the membrane by structural deformation of the protein.
As used in the present invention, "ammonium transporter", "adenine transporter" and "FMN/FAD transporter" are equivalent to transporter proteins, and have the property of specifically discharging only ammonium, adenine and FMN (flavin mononucleotide (flavin mononucleotide))/FAD (flavin adenine dinucleotide (flavin adenine dinucleotide)), respectively.
The transporter may be a gene encoding each transporter or a sequence having substantial identity thereto. As used herein, "substantial identity" refers to a sequence homology of 70% or more, 80% or more, 90% or more, or 98% or more between any other nucleotide sequence and each gene sequence, i.e., the base sequence or nucleotide sequence, when the nucleotide sequence and any other nucleotide sequence are aligned in a maximally corresponding manner for analysis.
The ammonium transport protein is encoded by using an amtB gene and comprises the amino acid sequence of SEQ ID NO. 3.
According to one embodiment of the present invention, the amino acid sequence of SEQ ID NO. 3 may be derived from wild-type E.coli.
The adenine transport protein is encoded by yicO gene and contains the amino acid sequence of SEQ ID NO. 7.
According to one embodiment of the present invention, the amino acid sequence of SEQ ID NO. 7 may be derived from wild-type E.coli.
The FMN/FAD transport protein is encoded by the yeeO gene and comprises the amino acid sequence of SEQ ID NO. 11.
According to one embodiment of the present invention, the amino acid sequence of SEQ ID NO. 11 may be derived from wild-type E.coli.
As used herein, a "variant" refers to a polypeptide in which one or more amino acids at the N-terminal, C-terminal and/or within the amino acid sequence of a particular gene are conservatively substituted (conservative substitution) and/or altered (modification) to differ from the amino acid sequence prior to mutation of the variant, but maintains functions or properties (properties). As used herein, "conservative substitutions" refer to the substitution of one amino acid for another that is structurally and/or chemically similar, with little or no effect on the activity of the protein or polypeptide. Furthermore, variants include variants with more than one N-terminal leader sequence or part of the transmembrane domain (transmembrane domain) deleted, or variants with a part deleted from the N-and/or C-terminus of the mature protein (protein). Such variants may have increased or unchanged or decreased ability compared to the polypeptide prior to mutation. In the present invention, variants may be used in combination with variants, alterations, variant polypeptides, variant proteins, variants, and the like.
The variant of the present invention is an ammonium transporter variant, which is an amino acid 363 in the amino acid sequence of SEQ ID NO. 3, i.e., glycine is substituted for aspartic acid, and may consist of the amino acid sequence of SEQ ID NO. 1.
The variant of the present invention is an adenine transporter variant in which tryptophan, which is the 136 th amino acid in the amino acid sequence of SEQ ID NO. 7, is replaced with a stop codon, and may be composed of the amino acid sequence of SEQ ID NO. 5.
The variant of the present invention is a FMN/FAD transporter variant in which glycine, which is the 272 th amino acid in the amino acid sequence of SEQ ID NO. 11, is replaced with glutamine, and may be composed of the amino acid sequence of SEQ ID NO. 9.
Another aspect of the invention provides polynucleotides encoding the ammonium transporter variants, adenine transporter variants, or FMN/FAD transporter variants described above.
The "polynucleotide" used in the present invention is a polymer of nucleotides (monomers) linked in a chain-like manner by covalent bonds, and is a DNA or RNA strand of a predetermined length or more, more specifically, a polynucleotide fragment encoding the variant.
The above polynucleotide may comprise a base sequence encoding the amino acid sequence of SEQ ID NO. 1, 5 or 9.
According to one embodiment of the present invention, the polynucleotide may comprise a base sequence represented by SEQ ID NO. 2, 6 or 10.
More specifically, the polynucleotide encoding the variant of the ammonium transporter includes a base sequence represented by SEQ ID NO. 2, the polynucleotide encoding the variant of the adenine transporter includes a base sequence represented by SEQ ID NO. 6, and the polynucleotide encoding the variant of the FMN/FAD transporter includes a base sequence represented by SEQ ID NO. 10.
Another aspect of the invention provides a vector comprising a polynucleotide encoding the ammonium transporter variant, adenine transporter variant, or FMN/FAD transporter variant described above.
In addition, another aspect of the present invention provides a transformant comprising the above ammonium transporter variant, adenine transporter variant or FMN/FAD transporter variant, or a polynucleotide thereof.
The term "vector" as used herein refers to any type of nucleic acid sequence transport structure used as a means for delivering and expressing a target gene into a host cell. Unless otherwise indicated, such vectors may refer to the insertion of a supported nucleic acid sequence into a host cell gene for expression and/or expression separately. Such vectors include the necessary regulatory elements operably linked for expression of the gene insert, "operably linked" means that the gene of interest and its regulatory sequences are functionally bound to each other and linked in a manner that enables gene expression, "regulatory elements" include promoters for carrying out transcription, any operator sequences for regulating transcription, sequences encoding suitable mRNA ribosome binding sites, and sequences regulating termination of transcription and translation.
The vector used in the present invention is not particularly limited as long as it can replicate in a host cell, and any vector known in the art can be used. Examples of the vector include plasmids, cosmids, viruses, and phages in their natural or recombinant state. For example, as phage vectors or cosmid vectors, we15, M13, λmbl3, λmbl4, λixi, λashii, λapii, λt10, λt11, charon4A, charon a, etc., and as plasmid vectors, pBR-based, pUC-based, pBluescriptII-based, pGEM-based, pTZ-based, pCL-based, pET-based, etc., are available, but not limited thereto.
The above vectors may be representatively constructed as vectors for cloning or vectors for expression. The vector for expression may use a conventional vector for expressing a foreign gene or protein in a plant, animal or microorganism in the art, and may be constructed by various methods well known in the art.
The recombinant vector can be constructed by taking a prokaryotic cell or a eukaryotic cell as a host. For example, when the vector used is an expression vector and prokaryotic cells are used as a host, a strong promoter (e.g., plλ promoter, CMV promoter, trp promoter, lac promoter, tac promoter, T7 promoter) that allows transcription to proceed generally contains a ribosome binding site for translation initiation and transcription/translation termination sequences. When eukaryotic cells are used as hosts, the replication origins to be initiated in eukaryotic cells contained in the vector include, but are not limited to, f1 replication origins, SV40 replication origins, pMB1 replication origins, adenovirus replication origins, AAV replication origins, BBV replication origins, and the like. In addition, promoters derived from mammalian cell genomes (e.g., metallothionein promoters) or promoters derived from mammalian viruses (e.g., adenovirus late promoter, vaccinia virus 7.5K promoter, SV40 promoter, cytomegalovirus promoter, tk promoter of HSV) may be utilized, and typically have polyadenylation sequences as transcription termination sequences.
The recombinant vector may include a selection marker for selecting transformants (host cells) transformed with the vector, and only cells expressing the selection marker may survive in the medium treated with the selection marker, thereby enabling selection of transformed cells. The selection markers include, but are not limited to, kanamycin, streptomycin, chloramphenicol, and the like.
By inserting the recombinant vector into a host cell, a transformant can be produced, which can be obtained by introducing the recombinant vector into an appropriate host cell. The host cell is a cell in which the above-described expression vector can be stably and continuously cloned or expressed, and any host cell known in the art can be used.
When a prokaryotic cell is transformed to produce a recombinant microorganism, E.coli JM109, E.coli BL21, E.coli RR1, E.coli LE392, E.coli B, E.coli X1776, E.coli W3110, E.coli XL1-Blue or other E.coli strains can be used as host cells; bacillus strains such as bacillus subtilis and bacillus thuringiensis; various intestinal bacteria and strains such as Salmonella typhimurium, serratia marcescens and Pseudomonas species, etc., but are not limited thereto.
In the case of transforming eukaryotic cells for the production of recombinant microorganisms, yeasts (e.g., saccharomyces cerevisiae), insect cells, plant cells, and animal cells, for example, sp2/0, CHO K1, CHO DG44, PER.C6, W138, BHK, COS7, 293, hepG2, huh7, 3T3, RIN, MDCK cell lines, etc., can be used as host cells, but are not limited thereto.
The term "transformation" as used herein refers to a phenomenon in which exogenous DNA is introduced into a host cell to artificially cause a gene change, and the term "transformant" refers to a host cell into which exogenous DNA is introduced and in which expression of a target gene is stably maintained.
In the above transformation, an appropriate vector introduction technique is selected according to the host cell, so that the target gene or a recombinant vector comprising the same can be expressed in the host cell. For example, the carrier may be introduced by electroporation (electro), thermal shock (heat-shock), calcium phosphate (CaPO) 4 ) Precipitated, calcium chloride (CaCl) 2 ) Precipitation, microinjection, polyethylene glycol (PEG),The DEAE-dextran method, the cationic liposome method, the lithium acetate-DMSO method, or a combination thereof is performed, but is not limited thereto. The transformed gene may be included as long as it can be expressed in the host cell, and is not limited to insertion into the chromosome of the host cell or to being located extrachromosomally.
The above transformant includes a cell transfected, transformed or infected with the recombinant vector according to the present invention in an organism or in a test tube, and may be used as the same term as a recombinant host cell, a recombinant cell or a recombinant microorganism.
According to one embodiment of the present invention, the transformant may be a strain of Escherichia.
Examples of the strain of the genus Escherichia include Escherichia coli (Escherichia coli), escherichia coli (Escherichia albertii), escherichia blattae (Escherichia blattae), escherichia fries (Escherichia fergusonii), escherichia hertz (Escherichia hermannii), and Escherichia wound (Escherichia vulneris), but are not limited thereto.
The transformant of the present invention may be a strain comprising the above-mentioned transporter variant or a polynucleotide encoding the same, or a strain comprising a vector containing the same; a strain expressing the transporter variant or polynucleotide; or a strain having an activity against the above-mentioned transporter variant, but is not limited thereto.
According to one embodiment of the present invention, the transformant may have L-aromatic amino acid productivity.
The transformant may have an L-aromatic amino acid-producing ability in nature or may be artificially provided with an L-aromatic amino acid-producing ability.
According to one embodiment of the present invention, the above transformant can be improved in L-aromatic amino acid productivity because the activity of an ammonium transporter variant, an adenine transporter variant or an FMN/FAD transporter is altered.
As used herein, "increased productivity" means that the productivity of L-aromatic amino acids is increased as compared to the parent strain. The parent strain refers to a wild-type strain or a mutant strain to be mutated, and includes a subject to be mutated directly or a subject to be transformed by a recombinant vector or the like. In the present invention, the parent strain may be a wild-type escherichia strain or an escherichia strain mutated from a wild-type strain.
The transformant according to the present invention shows an increased L-aromatic amino acid productivity as compared to the parent strain, particularly, an increase of more than 10% in L-aromatic amino acid productivity as compared to the parent strain, particularly, an increase of 10 to 80% (preferably 15 to 60%) by introducing an ammonium transporter variant, an adenine transporter variant or an FMN/FAD transporter variant, whereby the activity of each transporter is changed, and 3.5 to 20g of L-aromatic amino acid can be produced per 1 liter of strain culture broth.
Another aspect of the present invention provides a method for producing an L-aromatic amino acid, comprising the steps of: a step of culturing the transformant in a medium; and recovering the L-aromatic amino acid from the transformant or a medium in which the transformant is cultured.
The above-mentioned culture may be carried out according to a suitable medium and culture conditions known in the art, and the medium and culture conditions may be easily adjusted and used by those skilled in the art. Specifically, the medium may be a liquid medium, but is not limited thereto. The cultivation method may include, for example, batch cultivation (batch cultivation), continuous cultivation (continuous culture), fed-batch cultivation (fed-batch cultivation), or a combination thereof, but is not limited thereto.
According to one embodiment of the invention, the above-mentioned culture medium must meet the requirements of the particular strain in a suitable manner, and can be suitably deformed by a person skilled in the art. For the culture medium of the strain of the genus escherichia, reference may be made to a known document (Manual of Methods for General bacteriology, american Society for bacteriology, washington d.c., USA, 1981), but not limited thereto.
According to one embodiment of the present invention, the medium may contain various carbon sources, nitrogen sources and trace element components. As the carbon source which can be used, there are included sugars such as glucose, sucrose, lactose, fructose, maltose, starch, cellulose and the like and carbohydrates; oil and fat such as soybean oil, sunflower seed oil, castor seed oil, coconut oil and the like; fatty acids such as palmitic acid, stearic acid, and linoleic acid; alcohols such as glycerin and ethanol; organic acids such as acetic acid. These substances may be used alone or in the form of a mixture, but are not limited thereto. As nitrogen sources that can be used, peptone, yeast extract, broth, malt extract, corn steep liquor, soybean meal and urea or inorganic compounds, for example, ammonium sulfate, ammonium chloride, ammonium phosphate, ammonium carbonate and ammonium nitrate can be included. The nitrogen source may also be used alone or in the form of a mixture, but is not limited thereto. As the supply source of phosphorus that can be used, potassium dihydrogen phosphate or dipotassium hydrogen phosphate or corresponding sodium-containing salts may be included, but are not limited thereto. The medium may contain a metal salt such as magnesium sulfate or iron sulfate required for growth, but is not limited thereto. In addition, essential growth substances such as amino acids and vitamins may be contained. In addition, precursors suitable for the culture medium may be used. The above-mentioned medium or individual components may be added to the culture broth in batches or continuously by an appropriate means during the culture, but are not limited thereto.
According to an embodiment of the present invention, during the cultivation, a compound such as ammonium hydroxide, potassium hydroxide, ammonia, phosphoric acid, and sulfuric acid may be added to the microorganism culture solution in an appropriate manner to adjust the pH of the culture solution. In addition, during the culture, an antifoaming agent such as fatty acid polyglycol ester may be used to suppress bubble generation. Further, in order to maintain the aerobic state of the culture, oxygen or an oxygen-containing gas (e.g., air) may be injected into the culture. The temperature of the culture solution may be generally 20℃to 45℃and, for example, may be 25℃to 40 ℃. The incubation time may be continued until the desired throughput of the useful substance is obtained, for example, may be 10 to 160 hours.
According to one embodiment of the present invention, in the step of recovering an L-aromatic amino acid from the above-mentioned cultured transformant or the medium in which the transformant is cultured, the produced L-aromatic amino acid may be collected or recovered from the medium according to a culture method and by using an appropriate method known in the art. For example, centrifugation, filtration, extraction, spraying, drying, evaporation, precipitation, crystallization, electrophoresis, fractional dissolution (e.g., ammonium sulfate precipitation), chromatography (e.g., ion exchange, affinity, hydrophobicity, and size exclusion), and the like may be used, but are not limited thereto.
According to one embodiment of the present invention, in the step of recovering an L-aromatic amino acid, the medium may be centrifuged at a low speed to remove biomass, and the obtained supernatant may be separated by ion exchange chromatography.
According to one embodiment of the present invention, the step of recovering the L-aromatic amino acid may include a step of purifying the L-aromatic amino acid.
According to one embodiment of the present invention, the L-aromatic amino acid may be 1 or more selected from the group consisting of L-tryptophan, L-phenylalanine and L-tyrosine.
The transport protein variant according to the present invention alters protein activity by substituting one or more amino acids constituting the amino acid sequence of ammonium transport protein, adenine transport protein or FMN/FAD transport protein, so that a recombinant microorganism comprising the same can efficiently produce L-aromatic amino acids.
Drawings
Fig. 1 shows the structure of plasmid pDSG according to an embodiment of the invention.
FIG. 2 shows the structure of plasmid pDS9 according to an embodiment of the present invention.
Detailed Description
The present invention will be described in more detail below. However, such descriptions are merely provided for the purpose of facilitating understanding of the present invention, and the scope of the present invention is not limited to such exemplary descriptions.
Example 1 preparation of strains expressing variants of ammonium Transporter
In order to confirm the effect of the variant in which glycine 363 is substituted with aspartic acid in the amino acid sequence of ammonium transporter (SEQ ID NO: 3) on the production of L-aromatic amino acids, vectors expressing the above ammonium transporter variants and strains into which the above vectors were introduced were made. For gene insertion of the intra-strain ammonium transporter variants, plasmids pDSG and pDS9 were used and made as follows.
Here, the plasmid pDSG has an origin of replication which functions only in E.coli, an ampicillin resistance gene and a leader RNA (gRNA) expression mechanism. Plasmid pDS9 has an origin of replication which functions only in E.coli, with kanamycin resistance gene, the λRed gene (exo, bet and gam) and the CAS9 expression mechanism derived from Streptococcus pyogenes (Streptococcus pyogenes).
1-1 preparation of transformation vector pDSG-amtB (Gly 363 Asp)
By performing PCR using Escherichia coli MG1655 (KCTC 14419 BP) gDNA as a template, and using the primer pair of the primer 7 and the primer 9 and the primer pair of the primer 8 and the primer 10, respectively, an upstream (upstream) fragment of the 363 st amino acid variation of the Escherichia coli ambB gene encoding an ammonium transporter was obtained, and a downstream (downstream) fragment of the 363 st amino acid variation of the Escherichia coli ambB gene was obtained using the primer pair of the primer 11 and the primer 13 and the primer pair of the primer 12 and the primer 14. In this case, each of the upstream (upstream) and downstream (downstream) fragments includes a sequence in which glycine (Gly) which is amino acid residue 363 of the ambb gene is changed to aspartic acid (Asp). Here, the amplification conditions of Takara PrimeSTAR Max DNApolymerase, PCR were performed by repeating denaturation at 95℃for 10 seconds, annealing at 57℃for 15 seconds, and polymerization at 72℃for 10 seconds 30 times.
4 pDSG gene fragments were obtained by performing PCR using the plasmid pDSG as a template and the primer pairs of primer 3 and primer 5, the primer pair of primer 4 and primer 6, the primer pair of primer 15 and primer 1, and the primer pair of primer 16 and primer 2, respectively. In this case, each gene fragment was made to contain a gRNA sequence targeting Gly363 of the amtB gene. The gRNA selects the NGG pre 20mer of the sequence to be mutated. Here, the amplification conditions of Takara PrimeSTAR Max DNApolymerase, PCR were applied by repeating denaturation at 95℃for 10 seconds, annealing at 57℃for 15 seconds and polymerization at 72℃for 15 seconds 30 times.
Using self-assembled cloning (BioTechniques 51:55-56 (July 2011)), the obtained amino acids 363 of the amtB gene were cloned upstream (upstream) and downstream (downstream), and 4 pDSG gene fragments, thereby obtaining a recombinant plasmid designated as pDSG-amtB (Gly 363 Asp).
1-2 preparation of L-tryptophan or L-phenylalanine producing Strain into which ammonium Transporter variant amtB (Gly 363 Asp) was introduced
Coli KCCM13013P and KCCM10016 were used as parent strains for the production of L-tryptophan and L-phenylalanine producing strains.
Plasmid pDS9 was transformed into KCCM13013P strain or KCCM10016 strain 1 time, and after culturing in LB-Km (containing 25g/L LB liquid medium and 50mg/L kanamycin) solid medium, colonies with kanamycin resistance were selected. The pDSG-amtB (Gly 363 Asp) plasmid was transformed 2 times into selected colonies, cultured in LB-Amp & Km (containing 25g/L LB liquid medium, 100mg/L ampicillin and 50mg/L kanamycin) solid medium, and after ampicillin and kanamycin resistant colonies were selected, PCR was performed using primer pair of primer 17 and primer 18, thereby obtaining gene fragments. The amplification conditions for the polymerase using Takara PrimeSTAR Max DNApolymerase, PCR were repeated 30 times for denaturation at 95℃for 10 seconds, annealing at 57℃for 10 seconds, and polymerization at 72℃for 15 seconds. The sequence of the gene fragment obtained by using the primer pair of the primer 17 and the primer 18 was confirmed by the commission Macrogen.
The selected 2 transformants were subcultured 7 times in LB liquid medium, and colonies were selected in LB solid medium. Each colony was selectively cultured in LB, LB-Amp and LB-Km solid medium, respectively. Colonies that grew in LB solid medium and did not grow in LB-Amp and LB-Km solid medium were selected. The strains produced by the method described above were designated as KCCM13013P_pDSG-amtB (Gly 363 Asp) and KCCM10016_pDSG-amtB (Gly 363 Asp), respectively.
The primer sequences used in example 1 are shown in Table 1 below.
TABLE 1
Experimental example 1 evaluation of L-aromatic amino acid production ability of variant introduced with ammonium transport protein variant
The L-tryptophan or L-phenylalanine production capacity of the parent strain (KCCM 13013P and KCCM 10016) and the variant strain (KCCM 13013P_amtB (Gly 363 Asp) and KCCM10016_amtB (Gly 363 Asp)) into which the ammonium transporter variant was introduced were compared.
Each strain (parent strain or variant strain) was inoculated by 1% by volume and shake-cultured at 37℃for 72 hours under conditions of 200rpm in a 100mL flask containing 10mL of the tryptophan-producing medium or the phenylalanine-producing medium of Table 2 below. After the completion of the culture, the concentration of L-tryptophan or L-phenylalanine in the medium was measured by HPLC (Agilent), and the results are shown in tables 3 and 4 below, respectively.
TABLE 2
TABLE 3
TABLE 41
As shown in tables 3 and 4 above, it was confirmed that the variant strains KCCM13013P_amtB (Gly 363 Asp) and KCCM10016_amtB (Gly 363 Asp) into which the ammonium transporter variants were introduced had an increase in L-tryptophan and L-phenylalanine production by about 19% and 33%, respectively, as compared with the parent strains KCCM13013P and KCCM 10016.
EXAMPLE 2 production of strains expressing variant adenine transporter
In order to confirm the effect of the variant in which tryptophan at position 136 was replaced with a stop codon in the amino acid sequence of adenine transporter (SEQ ID NO: 7) on the production of L-aromatic amino acids, a vector expressing the variant of adenine transporter and a strain into which the vector was introduced were produced. For gene insertion of the adenine transporter variant in the strain, plasmids pDSG and pDS9 of example 1 were used and made as follows.
2-1 preparation of transformation vector pDSG-yicO (Trp 136 Stop)
By performing PCR using Escherichia coli MG1655 (KCTC 14419 BP) gDNA as a template and using the primer pair of the primer 7 and the primer 9 and the primer pair of the primer 8 and the primer 10, respectively, an upstream (upstream) fragment of the 136 th amino acid variation of the Escherichia coli yicO gene encoding adenine transporter was obtained, and a downstream (downstream) fragment of the 136 th amino acid variation of the Escherichia coli yicO gene was obtained using the primer pair of the primer 11 and the primer 13 and the primer pair of the primer 12 and the primer 14. In this case, the upstream (upstream) and downstream (downstream) fragments were each made to include a sequence in which tryptophan (Trp) as amino acid residue 136 of the yicO gene was changed to a Stop codon (Stop). Here, the amplification conditions of Takara PrimeSTAR Max DNApolymerase, PCR were performed by repeating denaturation at 95℃for 10 seconds, annealing at 57℃for 15 seconds, and polymerization at 72℃for 10 seconds 30 times.
4 pDSG gene fragments were obtained by performing PCR using the plasmid pDSG as a template and the primer pairs of primer 3 and primer 5, the primer pair of primer 4 and primer 6, the primer pair of primer 15 and primer 1, and the primer pair of primer 16 and primer 2, respectively. In this case, each gene fragment was made to contain a gRNA sequence targeting Trp No. 136 of the yicO gene. The gRNA selects the NGG pre 20mer of the sequence to be mutated. Here, the amplification conditions of Takara PrimeSTAR Max DNApolymerase, PCR were applied by repeating denaturation at 95℃for 10 seconds, annealing at 57℃for 15 seconds and polymerization at 72℃for 15 seconds 30 times.
The obtained 136 th amino acid of the yicO gene was cloned upstream (upstream) and downstream (downstream) and 4 pDSG gene fragments by a self-assembled cloning method (BioTechniques 51:55-56 (July 2011)), to obtain a recombinant plasmid, which was named as pDSG-yicO (Trp 136 Stop).
2-2 production of L-tryptophan or L-phenylalanine producing Strain into which adenine transporter variant yicO (Trp 136 Stop) was introduced
Coli KCCM13013P and KCCM10016 were used as parent strains for the production of L-tryptophan and L-phenylalanine producing strains.
Plasmid pDS9 was transformed into KCCM13013P strain or KCCM10016 strain 1 time, and after culturing in LB-Km (containing 25g/L LB liquid medium and 50mg/L kanamycin) solid medium, colonies with kanamycin resistance were selected. The pDSG-yicO (Trp 136 Stop) plasmid was transformed 2 times into a selected colony, cultured in LB-Amp & Km (containing 25g/L LB liquid medium, 100mg/L ampicillin and 50mg/L kanamycin) solid medium, and after ampicillin and kanamycin resistant colonies were selected, PCR was performed using primer pair of primer 17 and primer 18 to obtain a gene fragment. The amplification conditions for the polymerase using Takara PrimeSTAR Max DNApolymerase, PCR were repeated 30 times for denaturation at 95℃for 10 seconds, annealing at 57℃for 10 seconds, and polymerization at 72℃for 15 seconds. The sequence of the gene fragment obtained by using the primer pair of the primer 17 and the primer 18 was confirmed by the commission Macrogen.
The selected 2 transformants were subcultured 7 times in LB liquid medium, and colonies were selected in LB solid medium. Each colony was selectively cultured in LB, LB-Amp and LB-Km solid medium, respectively. Colonies that grew in LB solid medium and did not grow in LB-Amp and LB-Km solid medium were selected. The strains produced by the method described above were named KCCM13013P_yicO (Trp 136 Stop) and KCCM10016_yicO (Trp 136 Stop), respectively.
The primer sequences used in example 2 are shown in Table 5 below.
TABLE 5
Experimental example 2 evaluation of L-aromatic amino acid production ability of variant introduced with adenine transporter variant
The L-tryptophan or L-phenylalanine production capacity of the parent strain (KCCM 13013P and KCCM 10016) and the variant strain (KCCM 13013P_yiCO (Trp 136 Stop) and KCCM10016_yiCO (Trp 136 Stop)) into which the adenine transporter variant was introduced were compared. The concentrations of L-tryptophan and L-phenylalanine were measured in the same manner as in Experimental example 1, and the results are shown in tables 6 and 7, respectively, below.
TABLE 6
TABLE 7
As shown in tables 6 and 7 above, it was confirmed that the variant strains KCCM13013P_yicO (Trp 136 Stop) and KCCM10016_yicO (Trp 136 Stop) into which adenine transporter variants were introduced had an increase in L-tryptophan and L-phenylalanine production by about 26% and 19%, respectively, as compared with the parent strains KCCM13013P and KCCM 10016.
EXAMPLE 3 preparation of strains expressing FMN/FAD transporter variants
In order to confirm the effect of a variant in which glycine at position 272 in the amino acid sequence of FMN/FAD transporter (SEQ ID NO: 11) was replaced with glutamine on the production of L-aromatic amino acids, vectors expressing the above FMN/FAD transporter variants and strains into which the above vectors were introduced were prepared. For gene insertion of the intra-strain FMN/FAD transporter variant, plasmids pDSG and pDS9 were used in the same manner as in example 1 and were prepared as follows.
3-1 preparation of vector pDSG-yeeO (Gly 272 Glu) for transformation
By performing PCR using Escherichia coli MG1655 (KCTC 14419 BP) gDNA as a template, respectively, an upstream (upstream) fragment of amino acid variation of No. 272 of the Escherichia coli yeeO gene encoding FMN/FAD transporter was obtained by using the primer pair of primer 7 and primer 9 and the primer pair of primer 8 and primer 10, and a downstream (downstream) fragment of amino acid variation of No. 272 of the Escherichia coli yeeO gene was obtained by using the primer pair of primer 11 and primer 13 and the primer pair of primer 12 and primer 14. In this case, each of the upstream (upstream) and downstream (downstream) fragments includes a sequence in which glycine (Gly) which is the 272 th amino acid residue of the yeeO gene is changed to glutamine (Glu). Here, the amplification conditions of Takara PrimeSTAR Max DNApolymerase, PCR were performed by repeating denaturation at 95℃for 10 seconds, annealing at 57℃for 15 seconds, and polymerization at 72℃for 10 seconds 30 times.
4 pDSG gene fragments were obtained by performing PCR using the plasmid pDSG as a template and the primer pairs of primer 3 and primer 5, the primer pair of primer 4 and primer 6, the primer pair of primer 15 and primer 1, and the primer pair of primer 16 and primer 2, respectively. In this case, each gene fragment was made to contain a gRNA sequence targeting Gly No. 272 of the yeeO gene. The gRNA selects the NGG pre 20mer of the sequence to be mutated. Here, the amplification conditions of Takara PrimeSTAR Max DNApolymerase, PCR were applied by repeating denaturation at 95℃for 10 seconds, annealing at 57℃for 15 seconds and polymerization at 72℃for 15 seconds 30 times.
Using self-assembled cloning (BioTechniques 51:55-56 (July 2011)), the obtained upstream (upstream) and downstream (downstream) amino acids of the yeeO gene 272, and 4 pDSG gene fragments were cloned to obtain a recombinant plasmid designated as pDSG-yeeO (Gly 272 Glu).
3-2 preparation of L-tryptophan or L-phenylalanine producing Strain into which FMN/FAD transporter variant yeeO (Gly 272 Glu) was introduced
Coli KCCM13013P and KCCM10016 were used as parent strains for the production of L-tryptophan and L-phenylalanine producing strains.
Plasmid pDS9 was transformed into KCCM13013P strain or KCCM10016 strain 1 time, and after culturing in LB-Km (containing 25g/L LB liquid medium and 50mg/L kanamycin) solid medium, colonies with kanamycin resistance were selected. The pDSG-yeeO (Gly 272 Glu) plasmid was transformed 2 times into selected colonies, cultured in LB-Amp & Km (containing 25g/L LB liquid medium, 100mg/L ampicillin and 50mg/L kanamycin) solid medium, and after ampicillin and kanamycin resistant colonies were selected, PCR was performed using primer pair of primer 17 and primer 18, thereby obtaining gene fragments. The amplification conditions for the polymerase using Takara PrimeSTAR Max DNApolymerase, PCR were repeated 30 times for denaturation at 95℃for 10 seconds, annealing at 57℃for 10 seconds, and polymerization at 72℃for 15 seconds. The sequence of the gene fragment obtained by using the primer pair of the primer 17 and the primer 18 was confirmed by the commission Macrogen.
The selected 2 transformants were subcultured 7 times in LB liquid medium, and colonies were selected in LB solid medium. Each colony was selectively cultured in LB, LB-Amp and LB-Km solid medium, respectively. Colonies that grew in LB solid medium and did not grow in LB-Amp and LB-Km solid medium were selected. Strains produced by the method described above were designated as KCCM13013P_yeeO (Gly 272 Glu) and KCCM10016_yeeO (Gly 272 Glu), respectively.
The primer sequences used in example 3 are shown in Table 8 below.
TABLE 8
Experimental example 3 evaluation of L-aromatic amino acid production ability of variant introduced with FMN/FAD transporter variant
The L-tryptophan or L-phenylalanine production capacity of the parent strain (KCCM 13013P and KCCM 10016) and the variant strain (KCCM 13013P_yeeO (Gly 272 Glu) and KCCM10016_yeeO (Gly 272 Glu)) into which the FMN/FAD transporter variant was introduced were compared. The concentrations of L-tryptophan and L-phenylalanine were measured in the same manner as in Experimental example 1, and the results thereof are shown in tables 9 and 10, respectively, below.
TABLE 9
TABLE 10
As shown in tables 9 and 10 above, it was confirmed that the variant strains KCCM13013P_yeeO (Gly 272 Glu) and KCCM10016_yeeO (Gly 272 Glu) into which the FMN/FAD transporter variants were introduced had an increase in L-tryptophan and L-phenylalanine production by about 21% and 43%, respectively, as compared with the parent strains KCCM13013P and KCCM 10016.
The present invention has been studied so far about its preferred embodiments. Those skilled in the art to which the invention pertains will appreciate that the invention may be practiced in modified forms without deviating from the essential characteristics of the invention. Accordingly, the disclosed embodiments should be considered in an illustrative rather than a restrictive sense. The scope of the invention is indicated in the claims rather than in the foregoing description and all differences within the scope equivalent thereto are intended to be included in the present invention.
/>
/>
/>
Claims (7)
1. A FMN/FAD transporter variant comprises the amino acid sequence of SEQ ID NO. 9, wherein glycine 272 in the amino acid sequence of SEQ ID NO. 11 is replaced by glutamine.
2. A polynucleotide encoding the variant of claim 1.
3. A transformant comprising the variant of claim 1 or the polynucleotide of claim 2.
4. A transformant according to claim 3, wherein the transformant is a strain of Escherichia.
5. The transformant according to claim 3, wherein the transformant has L-aromatic amino acid productivity.
6. A method for producing an L-aromatic amino acid, comprising the steps of:
a step of culturing the transformant according to claim 3 in a medium; and
recovering the L-aromatic amino acid from the transformant or a medium in which the transformant is cultured.
7. The method according to claim 6, wherein the L-aromatic amino acid is 1 or more selected from the group consisting of L-tryptophan, L-phenylalanine and L-tyrosine.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR10-2022-0020012 | 2022-02-16 | ||
| KR1020220020012A KR20230123544A (en) | 2022-02-16 | 2022-02-16 | Novel variant of transporter and method for preparing L-aromatic amino acid using the same |
| PCT/KR2023/002096 WO2023158175A1 (en) | 2022-02-16 | 2023-02-14 | Novel transport protein variant and method for producing l-aromatic amino acid using same |
| CN202380008895.0A CN117043178A (en) | 2022-02-16 | 2023-02-14 | Novel variant of transport protein and method for producing L-aromatic amino acid using same |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202380008895.0A Division CN117043178A (en) | 2022-02-16 | 2023-02-14 | Novel variant of transport protein and method for producing L-aromatic amino acid using same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN117843736A true CN117843736A (en) | 2024-04-09 |
Family
ID=87578518
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202380008895.0A Pending CN117043178A (en) | 2022-02-16 | 2023-02-14 | Novel variant of transport protein and method for producing L-aromatic amino acid using same |
| CN202311729862.3A Pending CN117843736A (en) | 2022-02-16 | 2023-02-14 | Novel variant of transport protein and method for producing L-aromatic amino acid using same |
| CN202311729811.0A Pending CN117964724A (en) | 2022-02-16 | 2023-02-14 | Novel variant of transport protein and method for producing L-aromatic amino acid using same |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202380008895.0A Pending CN117043178A (en) | 2022-02-16 | 2023-02-14 | Novel variant of transport protein and method for producing L-aromatic amino acid using same |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202311729811.0A Pending CN117964724A (en) | 2022-02-16 | 2023-02-14 | Novel variant of transport protein and method for producing L-aromatic amino acid using same |
Country Status (3)
| Country | Link |
|---|---|
| KR (3) | KR20230123544A (en) |
| CN (3) | CN117043178A (en) |
| WO (1) | WO2023158175A1 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102251946B1 (en) * | 2019-10-31 | 2021-05-17 | 대상 주식회사 | Strain with Improved Aromatic Amino Acid Production Capacity by yeeO Gene Inactivation |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010090330A1 (en) * | 2009-02-09 | 2010-08-12 | 協和発酵バイオ株式会社 | Process for producing l-amino acid |
| KR101830002B1 (en) | 2016-10-11 | 2018-02-19 | 대상 주식회사 | Strain overexpressing l-tryptophan by enhancing sub substrates supply and process for producing l-tryptophan using the same |
| CN108949647B (en) * | 2018-04-19 | 2020-12-29 | 江南大学 | Engineering bacterium and application thereof in production of L-tyrosine |
| KR102251946B1 (en) * | 2019-10-31 | 2021-05-17 | 대상 주식회사 | Strain with Improved Aromatic Amino Acid Production Capacity by yeeO Gene Inactivation |
-
2022
- 2022-02-16 KR KR1020220020012A patent/KR20230123544A/en active Search and Examination
-
2023
- 2023-02-14 CN CN202380008895.0A patent/CN117043178A/en active Pending
- 2023-02-14 CN CN202311729862.3A patent/CN117843736A/en active Pending
- 2023-02-14 WO PCT/KR2023/002096 patent/WO2023158175A1/en active Application Filing
- 2023-02-14 CN CN202311729811.0A patent/CN117964724A/en active Pending
- 2023-07-27 KR KR1020230098039A patent/KR20230123452A/en active Application Filing
- 2023-07-27 KR KR1020230098040A patent/KR20230123453A/en active Application Filing
Also Published As
| Publication number | Publication date |
|---|---|
| CN117043178A (en) | 2023-11-10 |
| WO2023158175A9 (en) | 2023-09-21 |
| KR20230123453A (en) | 2023-08-23 |
| WO2023158175A1 (en) | 2023-08-24 |
| KR20230123544A (en) | 2023-08-24 |
| CN117964724A (en) | 2024-05-03 |
| KR20230123452A (en) | 2023-08-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN116606820B (en) | Novel variant of ATP synthase and method for producing L-aromatic amino acid using same | |
| CN117843736A (en) | Novel variant of transport protein and method for producing L-aromatic amino acid using same | |
| CN115044521B (en) | Corynebacterium glutamicum mutant strain having improved L-lysine productivity and method for producing L-lysine using same | |
| CN116940591A (en) | Sigma 38 novel variants and method for producing L-aromatic amino acids using same | |
| CN116606823A (en) | Novel variant of zinc-binding dehydrogenase and method for producing L-aromatic amino acid using same | |
| CN116917469A (en) | Novel variant of stress protein and method for producing L-aromatic amino acid using same | |
| CN117924440A (en) | Novel GlpM family protein variant and method for producing L-aromatic amino acid using same | |
| CN117925557A (en) | Novel variant of pyruvate kinase 2 and method for producing L-aromatic amino acid using same | |
| CN117964712A (en) | Qin prophage, novel variant of protein YnfQ and method for producing L-aromatic amino acid using the same | |
| KR102614733B1 (en) | Novel variant of phosphoenolpyruvate caboxylase and method for producing 5'-inosinic acid using the same | |
| KR101768390B1 (en) | A microorganism having enhanced L-lysine productivity and a method of producing L-lysine using the same | |
| CN117924441A (en) | Novel variant of DNA-binding transcription regulatory factor MalT and method for producing L-aromatic amino acid using the same | |
| KR102614734B1 (en) | Novel variant of 5-dehydro-2-deooxygluconokinase and method for producing 5'-inosinic acid using the same | |
| KR102636672B1 (en) | Mutant microorganism of Corynebacterium genus producing L-glutamic acid and method for producing L-glutamic acid using the same | |
| KR20240058000A (en) | Novel variant of Qin prophage; protein YnfQ and method for producing L-aromatic amino acid using the same | |
| KR20240058001A (en) | Novel variant of phenylalanine:H+ symporter PheP and method for producing L-aromatic amino acid using the same | |
| KR102572849B1 (en) | Mutant microorganism of Corynebacterium genus producing L-glutamic acid and method for producing L-glutamic acid using the same | |
| KR20240057999A (en) | Novel variant of GlpM family protein and method for producing L-aromatic amino acid using the same | |
| KR102572850B1 (en) | Mutant microorganism of Corynebacterium genus producing L-glutamic acid and method for producing L-glutamic acid using the same | |
| KR102636674B1 (en) | Mutant microorganism of Corynebacterium genus producing L-glutamic acid and method for producing L-glutamic acid using the same | |
| KR20240057981A (en) | Novel variant of pyruvate kinase 2 and method for producing L-aromatic amino acid using the same | |
| KR102546734B1 (en) | Mutant microorganism of Corynebacterium genus producing L-glutamic acid and method for producing L-glutamic acid using the same | |
| KR20240057998A (en) | Novel variant of DNA-binding transcriptional regulator MalT and method for producing L-aromatic amino acid using the same | |
| WO2024090884A1 (en) | Novel phenylalanine:h+ symporter phep variant, and method for producing l-aromatic amino acids using same | |
| WO2024014700A1 (en) | Corynebacterium sp. mutant microorganism producing l-glutamic acid and method for producing l-glutamic acid using same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |